Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Yesterday 18:33
BRIEF-Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data Oct 23 (Reuters) - Roche Holding AG ROPC.S:
ROCHE PRESENTS INTERIM PHASE III DATA SHOWING SEFAXERSEN SIGNIFICANTLY REDUCED PROTEINURIA IN PEOPLE WITH IGA NEPHROPATHY (IGAN)
ROCHE HOLDING AG - SEFAXERSEN ACHIEVED A STATISTICALLY SIGNIFICANT 43.1% REDUCTION IN PROTEINURIA
ROCHE-TREATMENT EFFECT IN ALL PRESPECIFIED SUBGROUPS CONSISTENT WITH CLINICALLY MEANINGFUL REDUCTIONS IN PROTEINURIA SHOWN IN PRIMARY ENDPOINT RESULTS
ROCHE: SEFAXERSEN WAS WELL TOLERATED WITH SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED PHASE II STUDY, EXHIBITING NO NEW SAFETY SIGNALS
Source text: ID:nGNE9whWdG
Further company coverage: ROPC.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey